Syngene International Stock Price Analysis May 2026
Syngene International Limited, incorporated in 1993 and listed on Indian exchanges since August 2015, is India’s pre-eminent integrated Contract Research, Development and Manufacturing Organisation (CRDMO). A subsidiary of Kiran Mazumdar-Shaw’s Biocon group, Syngene operates across the full drug discovery and development continuum — from early discovery chemistry and biology through pre-clinical development, clinical trial support, API synthesis, and commercial biologics manufacturing — all on a single integrated platform. Operations span approximately 2.2 million sq. ft. of facilities across Bengaluru (primary hub), Hyderabad, and Mangalore, with a newly acquired biologics facility in Baltimore, Maryland (USA).
Syngene’s model is differentiated by the depth of its scientific capabilities — spanning small molecules, large molecule biologics, peptides, and oligonucleotides — and by its integrated end-to-end platform that gives global innovators a single-window outsourcing partner from early discovery through commercial supply. The dedicated R&D centre model (long-term exclusive arrangements with marquee clients such as Bristol-Myers Squibb, AstraZeneca, Herbalife, and Abbott) provides revenue visibility and relationship stickiness, while the FFS (fee-for-service) book adds scalability. The critical vulnerability, starkly exposed in FY26, is single-client concentration in its commercial biologics manufacturing segment.
| Metric (₹ Cr, Consol.) | FY22 | FY23 | FY24 | FY25 | FY26 | YoY Δ |
|---|---|---|---|---|---|---|
| Revenue from Operations | 2,497 | 3,002 | 3,306 | 3,642 | 3,739 | +3% |
| EBITDA | 711 | 870 | 1,021 | 1,044 | 918 | −12% |
| EBITDA Margin (%) | 28.5% | 29.0% | 30.9% | 28.6% | 24.6% | −400 bps |
| Depreciation & Amortisation | 220 | 250 | 280 | 300 | 325 | +8% |
| EBIT | 491 | 620 | 741 | 744 | 593 | −20% |
| Interest & Finance Costs | 28 | 30 | 28 | 24 | 30 | +25% |
| PBT | 463 | 590 | 713 | 720 | 563 | −22% |
| Tax | 85 | 105 | 120 | 138 | 183 | +33% |
| PAT (reported) | 378 | 485 | 593 | 496 | 317 | −36% |
| EPS (₹) | 9.4 | 12.1 | 14.8 | 12.3 | 7.9 | −36% |
| ROCE (%) | 13.5% | 15.8% | 17.2% | 14.5% | 10.5% | ↓ |
| ROE (%) | 10.5% | 12.2% | 14.1% | 10.0% | 6.7% | ↓ |
| Capex (₹ Cr) | 380 | 490 | 650 | 520 | 480 | −8% |
| Net Debt / (Cash) | Net Cash | Net Cash | Net Cash | Net Cash | Net Cash | — |
Quarterly trajectory in FY26 tells a worsening mid-year story with sequential recovery in Q4. Q1 FY26 (Jun’25) was a bright spot with PAT of ₹87 Cr (+15% YoY), followed by steady erosion — Q2 FY26 PAT ₹67 Cr (−37% YoY), Q3 FY26 PAT ₹15 Cr (an alarming −89% YoY due to biologics revenue collapse), and a partial recovery in Q4 FY26 with revenue of ₹1,037 Cr (+2% YoY, +13% QoQ) and PAT of ₹148 Cr (−16% YoY). The Q4 trajectory at least signals the trough has passed.
The DCF values Syngene at approximately ₹476/share under a base-case scenario that prices in a delayed recovery in the biologics manufacturing segment, with normalised EBITDA margins reverting to 28–30% by FY28-29 as the client destocking headwind abates and new capacity is absorbed. The stock at CMP of ₹393 already trades at a modest discount to this intrinsic value, implying a margin of safety has emerged — though it is not yet deep enough to justify an aggressive Buy thesis absent clarity on the biologics client trajectory in FY27.
| Company | Model | Mkt Cap (Cr) | Rev TTM (Cr) | EBITDA Mgn | P/E TTM | EV/EBITDA | Rev Growth | ROE |
|---|---|---|---|---|---|---|---|---|
| Syngene Intl. | CRDMO | 15,800 | 3,739 | 24.6% | ~50× | ~18× | 3% | 6.7% |
| Divi’s Laboratories | CDMO/API | 1,10,000 | 9,250 | 35% | ~60× | ~38× | 15% | 16% |
| Laurus Labs | CDMO/API | 22,000 | 5,400 | 22% | ~40× | ~18× | 8% | 8% |
| PI Industries (CS) | CSM/Agro | 42,000 | 8,100 | 22% | ~28× | ~20× | 12% | 18% |
| Suven Life Sciences | CDMO (niche) | 6,200 | 340 | ~55% | ~80× | ~50× | 20% | 14% |
| Biocon Biologics | Biosimilars/Mfg | 23,000 | 4,200 | 16% | NM | ~22× | 18% | NM |
On a P/E basis Syngene appears expensive at ~50x given the 36% PAT decline in FY26, but this is a distorted earnings year. On a normalised FY28E earnings power basis (~₹650–700 Cr PAT, implying EPS of ₹16–17), the stock at ₹393 trades at ~23–24x forward earnings, a level that represents a significant de-rating from its historical 35–45x band and begins to look relatively compelling for a quality CRDMO franchise. On an EV/EBITDA basis (~18x FY26), Syngene is in-line with mid-tier peers like Laurus Labs, a substantial discount to Divi’s and Suven — peers with cleaner near-term earnings profiles. This discount is justified partly by execution risk but creates a re-rating runway as biologics headwinds normalise.
At 3.4× P/BV, Syngene reflects significant goodwill for its scientific platform, client relationships, regulatory track record, and brand. This is reasonable for a quality service business with irreplaceable intangibles — Syngene’s scientific team of 6,000+ experts, 400+ joint patents, and multi-decade global pharma relationships are off-balance-sheet value. The Baltimore facility acquired at $36.5 Mn (≈₹300 Cr) is carried at cost; its strategic US biologics manufacturing option value is not fully reflected in book. Asset-based valuation alone yields a floor price of ~₹117 (book value) — a useful downside anchor, not a primary valuation.
EPV of ₹149 treats the company as a static franchise earning normalised returns, with no terminal growth premium. The gap between EPV (~₹149) and CMP (₹393) represents the market’s growth premium — it implies investors are paying ~2.6× for the optionality of Syngene’s platform expansion, CRDMO market share gains, and US biologics buildout. This is not unreasonable for a company with structural secular tailwinds in pharma outsourcing, but it does establish the maximum downside scenario if growth completely stalls.
| Segment | Revenue FY28E (Cr) | EBITDA Mgn | EBITDA (Cr) | EV/EBITDA Multiple | Segment Value (Cr) |
|---|---|---|---|---|---|
| Research Services (FFS + Dedicated) | 2,200 | 30% | 660 | 22× | 14,520 |
| Development Services (Small Mol.) | 1,100 | 28% | 308 | 20× | 6,160 |
| Manufacturing (Biologics + API) | 1,100 | 24% | 264 | 16× | 4,224 |
| US Biologics (Baltimore, option value) | — | — | — | — | 600 |
| Enterprise Value (SOTP) | 4,400 | — | 1,232 | — | 25,504 |
| Less: Net Debt | — | — | — | — | (500) |
| Equity Value / Share | — | — | — | — | ~₹625 |
The SOTP approach, which is meaningful for Syngene given its three distinct service lines with differentiated margin profiles and growth rates, yields a per-share equity value of ~₹625. Manufacturing gets a discounted multiple (16×) reflecting the client concentration risk, while research services command premium multiples (22×) given FFS recurring characteristics and deep client stickiness. The US biologics facility carries a conservative ₹600 Cr option value given its early-stage operational status.
The CMP of ₹393 sits in the lower end of the Accumulate / Core Buy Zone — not quite the aggressive-load zone, but firmly within a range where initiating or building a position is rational. The stock has corrected ~49% from its 52-week high of ₹760, reflecting the biologics client shock. At ₹370–410, an investor is buying one of India’s only integrated CRDMO platforms at ~23–25× normalised FY28 earnings — a meaningful discount to its 5-year average PE of ~38×.
The asymmetry at CMP is modestly favourable — downside of ~20% in the bear case versus upside of ~67–80% in the bull case over an 18–24 month horizon. The key binary catalyst is whether the large biologics client de-stocking resolves in FY27 or extends beyond. Management guidance post-FY26 results (delivered April 29, 2026) will be the decisive signal for position sizing.
Progressive profit-booking is recommended as the stock recovers, rather than a single exit. The first trim zone (₹520–550) represents a re-rating to ~30–32× normalised FY28E EPS — fair, not expensive. Above ₹620, the stock would be pricing in near-perfection on a biologics recovery and US ramp-up simultaneously, making it prudent to reduce position to a tracking stake. A full exit above ₹650 is warranted unless quarterly results in FY27 demonstrate the recovery is materially ahead of base-case expectations.
The sell-without-waiting scenario is triggered if any of the following occur: (a) the large biologics client permanently shifts its commercial manufacturing program to an in-house or China-based supplier, structurally reducing Syngene’s manufacturing revenue base by 20%+ indefinitely; (b) a Form 483 or warning letter from USFDA disrupts Syngene’s impeccable regulatory reputation and leads to customer audits pausing new business; (c) the Biocon group parent faces a structural liquidity or governance crisis that creates contagion risk for Syngene’s operations or management stability; or (d) management FY27 guidance signals EBITDA margin remaining below 24% despite biologics recovery, suggesting structural cost inflation.
The $36.5 Mn acquisition of the Baltimore facility from Emergent BioSolutions positions Syngene as one of the very few Indian CRDMO players with US soil biologics manufacturing. This de-risks the China supply chain thesis for US pharma clients and aligns with the Biosecure Act tailwind. Revenue contribution could reach $30–50 Mn by FY28–29.
Biologics Unit III in Bengaluru adds bioreactor and microbial manufacturing capacity for next-generation drugs. The new peptide laboratory complements growing GLP-1 and oncology biologics demand. Syngene has 6,000+ scientists capable of supporting complex modality expansion including ADCs, gene therapies, and mRNA — all structurally growth areas.
US Biosecure Act legislation creating pressure on pharma companies to diversify away from Chinese CDMO players (WuXi, etc.) creates a structural multi-year demand tailwind for Indian CRDMOs. Syngene, with its 30-year pedigree, institutional client relationships, and regulatory track record, is uniquely positioned to capture this outsourcing re-routing.
Leadership continuity requires watching: Peter Bains steps down as MD & CEO on June 30, 2026, with Siddharth Mittal taking charge from July 1, 2026. Kiran Mazumdar-Shaw transitions to Executive Chairperson from April 1, 2026 for a five-year term, ensuring strategic continuity at the board level. Mittal’s background (needs tracking post-announcement) will be key in assessing whether the transition is a strategic catalyst or a disruption risk.
The weighted intrinsic value of ~₹511 per share implies an upside of approximately 30% from the current market price of ₹393. Given the earnings uncertainty in FY27, we apply a 15% discount for execution risk to derive a conservative 12–18 month price target range of ₹520 – ₹580 (at full recovery, the bull-case SOTP supports ₹625+). This positions the stock as an Accumulate — not yet a Strong Buy, pending Q1 FY27 commentary on biologics client recovery — with a compelling risk-reward for investors with a 18–24 month horizon.
